revumenib 110 MG Oral Tablet
- RxCUI
- 2698331
- RxNorm name
- revumenib 110 MG Oral Tablet
- Display name
- revumenib 110 MG Oral Tablet
- Full name
- revumenib 110 MG Oral Tablet
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:03
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Revuforj | REVUMENIB | Syndax Pharmaceuticals, Inc. | 6eb3cdbc-0e74-477d-82d6-3bb172d3f63f | 2026-02-04 | Boxed warning, Warnings, Adverse reactions | 2698331 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 6eb3cdbc-0e74-477d-82d6-3bb172d3f63f | revumenib 110 MG Oral Tablet [PSN] · revumenib 110 MG Oral Tablet [SCD] · revumenib 110 MG (as revumenib citrate 146.5 MG) Oral Tablet [SY] | 3 | 5 | These highlights do not include all the information needed to use REVUFORJ safely and effectively. See full prescribing information for REVUFORJ. REVUFORJ (revumenib) tablets for oral use Initial U.S. Approval: 2024 | 20260204 |